Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic

Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic

 

RELEASE DATE
23-Aug-2010
REGION
North America
Deliverable Type
Market Research
Research Code: 9561-00-AC-00-00
SKU: HC00601-NA-MR_04074
AvailableYesPDF Download

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC00601-NA-MR_04074

$1,500.00

$1,125.00save 25 %

DownloadLink
ENQUIRE NOW

Description

This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for B•R•A•H•M•S, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.

Table of Contents

This week's issue:

This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for BRAHMS, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.
More Information
Deliverable Type Market Research
No Index No
Podcast No
Industries Healthcare
WIP Number 9561-00-AC-00-00
Is Prebook No